To include your compound in the COVID-19 Resource Center, submit it here.

ICER finds asthma mAbs to be not cost-effective

In a draft evidence report, the Institute for Clinical and Economic Review (ICER) found that five biologics approved or in testing to treat asthma were not cost-effective compared with standard of care (SOC) therapies despite all showing comparable or better efficacy to SOC.

The review evaluated benefits and costs

Read the full 481 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE